Biosimilar Filgrastim Recommended for Approval in US Biosimilar Filgrastim Recommended for Approval in US

A biosimilar filgrastim (Novartis) has been recommended for approval in the US, after it was found not clinically different from Amgen's Neupogen. News Alerts
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news